T-knife Therapeutics
PrivateLast Round
Series B
Aug 2, 2021
Total Funding Raised
$207.18M
Company Overview
T-knife Therapeutics is a biopharmaceutical company that develops next-generation T cell receptor (TCR) engineered therapies to treat solid tumor cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
T-knife Therapeutics Comparables
Compare T-knife Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anocca | 83% | |
| Captain T Cell GmbH | 79% | |
| Immatics N.V. | 79% | |
T-knife Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 2, 2021 | ||||
| Series A | Aug 6, 2020 |
Key People
Founding team and executive leadership
T-knife Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Columbus Ventures | Series A |
| RA Capital Management | Series B, Series A |
| Sixty Degree Capital | Series B |
| EQT Life Sciences | Series B |
| Andera Partners | Seed, Series B, Series A |
| Fidelity Management & Research Company | Series B |
| Versant Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 16, 2026
Phase 1 trial initiated for CRISPR T cell therapy.
- Mar 3, 2026
Phase 1 trial for TK-6302 approved in Europe.
T-knife Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about T-knife Therapeutics's valuation, stock price, and market status.